This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Biedenbach, D. J.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Biedenbach, D. J.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, March 2007, p. 998-1004, Vol. 45, No. 3
0095-1137/07/$08.00+0     doi:10.1128/JCM.02368-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Activity of Dalbavancin Tested against Staphylococcus spp. and ß-Hemolytic Streptococcus spp. Isolated from 52 Geographically Diverse Medical Centers in the United States{triangledown}

Douglas J. Biedenbach,1* James E. Ross,1 Thomas R. Fritsche,1 Helio S. Sader,1,2 and Ronald N. Jones1,3

JMI Laboratories, North Liberty, Iowa,1 Universidade Federal de Sao Paulo, Sao Paulo, Brazil,2 Tufts University School of Medicine, Boston, Massachusetts3

Received 22 November 2006/ Returned for modification 18 December 2006/ Accepted 26 December 2006

Dalbavancin is a lipoglycopeptide antimicrobial agent with a potency significantly better than that of vancomycin when tested against staphylococci and streptococci. These two pathogens are common causes of skin and skin structure infections (SSSIs), and dalbavancin has been approved for the treatment of moderate to severe SSSIs. This study generated susceptibility data for staphylococci and ß-hemolytic streptococci from 52 U.S. medical centers that locally tested dalbavancin, vancomycin, and other antimicrobial class representatives to assess the potency of dalbavancin and the overall contemporary activities of commonly prescribed agents. Locally generated data showed that oxacillin-resistant staphylococci (57.0% overall) had slightly higher dalbavancin MIC90 values (0.19 µg/ml) than oxacillin-susceptible strains (0.125 µg/ml). This potency was 8- to 16-fold greater than that for vancomycin. ß-Hemolytic streptococci had MIC90 values ranging between ≤0.016 and 0.064 µg/ml (highest for group B isolates). Levofloxacin, gentamicin, and tetracycline were active against oxacillin-susceptible staphylococci (82 to 99% susceptible), with lower susceptibility rates seen for the oxacillin-resistant strains. Linezolid coverage was >98% against staphylococci. Erythromycin resistance was high for staphylococci (30.6 to 94.1%) with inducible clindamycin resistance rates of 26.0% and 55.0% for oxacillin-susceptible and -resistant Staphylococcus aureus, respectively. ß-Hemolytic streptococci had a 20.2% erythromycin resistance rate and a 60% inducible clindamycin resistance rate but were highly susceptible to other tested agents. Etest reading errors were apparent and skewed results towards slightly higher dalbavancin MICs, requiring further education on how to interpret Etest method results for this compound. Current disk diffusion breakpoint criteria for oxacillin susceptibility for S. aureus showed a very-major-error rate of 2.3% and only a 0.9% minor-error rate when cefoxitin was used to predict oxacillin susceptibility. Dalbavancin demonstrated excellent potency and activity (100% susceptibility at proposed breakpoints) against common causes of SSSI pathogens in this U.S. multicenter study sample.

* Corresponding author. Mailing address: JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317. Phone: (319) 665-3370. Fax: (319) 665-3371. E-mail: douglas-biedenbach{at}jmilabs.com.

{triangledown} Published ahead of print on 10 January 2007.

Journal of Clinical Microbiology, March 2007, p. 998-1004, Vol. 45, No. 3
0095-1137/07/$08.00+0     doi:10.1128/JCM.02368-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Biedenbach, D. J., Bell, J. M., Sader, H. S., Turnidge, J. D., Jones, R. N. (2009). Activities of Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial Isolates. Antimicrob. Agents Chemother. 53: 1260-1263 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»